Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
151.26
-2.11 (-1.38%)
Jul 14, 2026, 12:08 PM EDT - Market open
Revenue Breakdown
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Mar '23 Mar 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 | Jun '22 Jun 30, 2022 | Mar '22 Mar 31, 2022 | Dec '21 Dec 31, 2021 | Sep '21 Sep 30, 2021 | Jun '21 Jun 30, 2021 | Mar '21 Mar 31, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 30, 2020 | Jun '20 Jun 30, 2020 |
Innovative Medicines Revenue | 13.11B | |||||||||||||||||||||||
Innovative Medicines Revenue Growth | -0.91% | |||||||||||||||||||||||
Revenue (Other) | 411.00M | |||||||||||||||||||||||
Revenue (Total) | 13.52B | |||||||||||||||||||||||
Revenue (Total) Growth | -0.70% |
Revenue by Geography
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Mar '23 Mar 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 | Jun '22 Jun 30, 2022 | Mar '22 Mar 31, 2022 | Dec '21 Dec 31, 2021 | Sep '21 Sep 30, 2021 | Jun '21 Jun 30, 2021 | Mar '21 Mar 31, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 30, 2020 | Jun '20 Jun 30, 2020 |
United States Revenue (Post-Q2 2023 Reporting) | 4.96B | |||||||||||||||||||||||
United States Revenue (Post-Q2 2023 Reporting) Growth | -13.18% | |||||||||||||||||||||||
Europe Revenue (Post-Q2 2023 Reporting) | 4.19B | |||||||||||||||||||||||
Europe Revenue (Post-Q2 2023 Reporting) Growth | 7.20% | |||||||||||||||||||||||
Asia/Africa/Australasia Revenue (Post-Q2 2023 Reporting) | 3.02B | |||||||||||||||||||||||
Asia/Africa/Australasia Revenue (Post-Q2 2023 Reporting) Growth | 8.95% | |||||||||||||||||||||||
Canada and Latin America Revenue (Post-Q2 2023 Reporting) | 948.00M | |||||||||||||||||||||||
Canada and Latin America Revenue (Post-Q2 2023 Reporting) Growth | 12.32% | |||||||||||||||||||||||
Revenue (Other) | 411.00M | |||||||||||||||||||||||
Revenue (Total) | 13.52B | |||||||||||||||||||||||
Revenue (Total) Growth | -0.70% |
Revenue Breakdown 2
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Mar '23 Mar 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 | Jun '22 Jun 30, 2022 | Mar '22 Mar 31, 2022 | Dec '21 Dec 31, 2021 | Sep '21 Sep 30, 2021 | Jun '21 Jun 30, 2021 | Mar '21 Mar 31, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 30, 2020 | Jun '20 Jun 30, 2020 |
Cardiovascular, Renal And Metabolic Revenue | 1.77B | |||||||||||||||||||||||
Cardiovascular, Renal And Metabolic Revenue Growth | -29.59% | |||||||||||||||||||||||
Immunology Revenue | 2.47B | |||||||||||||||||||||||
Immunology Revenue Growth | 2.37% | |||||||||||||||||||||||
Neuroscience Revenue | 1.56B | |||||||||||||||||||||||
Neuroscience Revenue Growth | 19.89% | |||||||||||||||||||||||
Oncology Revenue | 4.02B | |||||||||||||||||||||||
Oncology Revenue Growth | 39.47% | |||||||||||||||||||||||
Established Brands Revenue | 3.29B | |||||||||||||||||||||||
Established Brands Revenue Growth | -20.12% | |||||||||||||||||||||||
Revenue (Total) | 13.52B | |||||||||||||||||||||||
Revenue (Total) Growth | -0.70% |
Key Performance Indicators
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Mar '23 Mar 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 | Jun '22 Jun 30, 2022 | Mar '22 Mar 31, 2022 | Dec '21 Dec 31, 2021 | Sep '21 Sep 30, 2021 | Jun '21 Jun 30, 2021 | Mar '21 Mar 31, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 30, 2020 | Jun '20 Jun 30, 2020 |
Cosentyx Revenue | 1.57B | |||||||||||||||||||||||
Cosentyx Revenue Growth | 2.09% | |||||||||||||||||||||||
Entresto Revenue | 1.31B | |||||||||||||||||||||||
Entresto Revenue Growth | -42.28% | |||||||||||||||||||||||
Tasigna Revenue | 155.00M | |||||||||||||||||||||||
Tasigna Revenue Growth | -58.89% | |||||||||||||||||||||||
Lucentis Revenue | 104.00M | |||||||||||||||||||||||
Lucentis Revenue Growth | -44.97% |